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Abstract We constructed a synthetic gene encoding the published amino acid sequence of DTx from Dendroaspis angusticeps, a ligand of voltage- 
dependent postassium channels that facilitates neurotransmitter release. We expressed it in Escherichia coli as a fusion protein secreted in the culture 
medium. The recombinant DTx was generated in vitro by chemical treatment and recovered as two isoforms. One of them (rDTx), like the venom 
toxin, has an N-terminal pyroglutamate whereas the other (rQDTx) has a free N-terminal glutamine. Chromatographic differences between rDTx 
and natural DTx led us to re-examine the amino acid sequence of natural DTx. In contrast to what was previously published, position 12 was an 
Asp and not Asn. Despite this difference, rDTx and DTx had similar toxicity in mice and binding affinity to synaptosomes, uggesting that residue 
12 is not important for DTx function. Nor is the N-terminal residue implicated inDTx function since rDTx and QDTx also had similar biological 
activities. We also synthesized and expressed a mutant of the DTx gene in which the lysine triplet 28-30 was changed into Ala-Ala-Gly. The two 
resulting recombinant isoforms exhibited only small decreases in biological activity, excluding the possibility that the positively charged lysine triplet 
28-30 of DTx is directly involved in the toxin functional site. 
Key words: Potassium channel; Recombinant snake toxin; Site directed mutagenesis 
1. Introduction 
Dendrotoxins are small proteins (57-60 amino acids) isolated 
from mamba venoms which facilitate the release of neurotrans- 
mitters at peripheral (l-3) and central [4] synapses by blocking 
certain voltage-dependent potassium channels to which they 
bind with high affinity. They constitute important tools for 
isolating and studying subtypes of potassium channels (for re- 
view see [5]). Seven dendrotoxins have been purified from ven- 
oms of the snakes belonging to the Dendroaspis genus. Their 
amino acid sequences have been determined either totally or 
partially [6-91 and the three-dimensional structures of a-den- 
drotoxin (DTx) from Dendrouspis angusticeps [lo] and den- 
drotoxins I and K (DpI and DpK) from Dendroaspis polyrepis 
[11,12] have been solved. All these proteins are structurally 
similar to Kunitz-type serine protease inhibitors, such as the 
bovine pancreatic trypsin inhibitor BPTI [ 10,131. 
The site by which these toxins interact with their target is not 
known. However, on the basis of amino acid sequence compar- 
isons between dendrotoxins and non-toxic homologues, it was 
often proposed [14-161 that the conserved positively charged 
residues, and in particular the lysine triplet found in position 
28-30 in DTx and DpI, might interact with a corresponding 
negatively charged region on the potassium channel. Consistent 
with an electrostatic interaction between the two partners, it 
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Expression of DTx was previously described in a preliminary report 
abstract of the Xth Meeting on Toxinology which was held in Paris on 
2-4 September 1992. 
has been shown recently that the DTx binding site on rat 
brain potassium channel is located in an extracellular domain 
which includes an essential negatively charged residue ([ 17,181, 
for review see [19]). 
The aim of this work was to probe the functional role of the 
lysine triplet 28-30 of DTx by protein engineering. This was 
achieved in three steps. First, we constructed a synthetic gene 
encoding the published amino acid sequence of DTx from 
Dendroaspis angusticeps [7], expressed it at a fusion protein in 
E. coli according to a convenient approach which previously 
proved to be efficient for producing correctly folded disulfide- 
containing proteins [20,21]. Second, the recombinant DTx was 
generated by chemical cleavage of the fusion protein and exam- 
ined regarding its physicochemical and biological properties 
under both in vivo and in vitro conditions. Third, we synthe- 
sized an additional gene in which the lysine triplet 28-30 of DTx 
was replaced by Ala-Ala-Gly, and generated the recombinant 
mutant using the same expression system employed for the 
wild-type DTx. Examination of the biological properties of the 
mutant provides evidence that the lysine triplet is not essential 
for binding of DTx to potassium channels. 
2. Materials and methods 
2.1. Materials 
Enzymes were purchased from Boehringer-Mannheim. Oligonucleo- 
tides were synthesized on an Applied Biosystems 381A. Amino acid 
composition analyses were performed using an Applied Biosystems 
device (420A Derivatizer and 130A Separation system) and N-terminal 
sequencing using the Applied Biosystems equencer (477A Protein Se- 
quencer) on line with the PTH analyser (120A Analyser). Masses were 
determined using an electrospray mass spectrometer (Analytica, Bran- 
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dichourauh. 
. Dichroic spectra were recorded on a Jobin-Yvon CD6 
SDS-PAGE were performed using the PhastSystem from 
Pharmacia. Expression vector pEZZ 18 [22,23] was generously 
provided by Prof. Mathias Uhltn (Royal Institute of Technology, 
Stockholm) and the bacterial host for expression was E. coli HB 101 
[24]. Biolafitte fermentor (St. Germain en Laye, France) and culture 
medium from Difco (USA) were used for production of recombinant 
proteins. Natural DTx used as a standard-was either a gift from Dr. 
Evert Karlsson (Uppsala University, Sweden) or was purified in our 
laboratory from venom provided by Latoxan (Rosans, France). 
2.2. Molecular biology 
DNA manipulation, transformation and plasmid purification were 
performed according to published procedures [25]. Sequences of both 
the synthetic genes and the expression vector were checked by single- 
and double-stranded sequencing [26,27]. 
2.3. Synthetic gene assembly 
A 213 bp DNA fragment encoding the published DTx sequence [7] 
was synthesized as follows. Twelve oligomers ranging in length from 
26 to 48 nucleotides were synthesized and purified [25]. Six duplexes 
resulting from annealing of complementary oligonucleotides (100 pmol 
of each) were ligated three x three to generate two segments having, 
respectively, 119 and 94 bp. These two segments were finally ligated to 
yield the complete synthetic gene flanked by EcoRI and PstI restriction 
sites. It was purified, excised and then inserted into Ml 3mpl8 to assess 
its nucleotide sequence. The strategy to construct he mutant gene was 
similar except that one duplex was substituted by a mutated one in 
which the codons for the three consecutive Lys at positions 28-30 of 
the toxin were replaced by codons encoding the triplet Ala-Ala-Gly. 
2.4. Expression vector construction 
Following biological amplification in bacteria, the two synthetic 
genes were excised from M 13mpl8 and inserted in the expression vector 
pEZZ 18 (Pharmacia) using EcoRl and Pstl restriction sites. The 
resulting vectors were checked by double-stranded sequencing and used 
to transform E. coli HBlOl strain for protein production. 
2.5. Production and purijication of the fusion recombinant proteins 
Transformed bacteria were grown according to [20] in 4 or 12 1 of 
culture medium. When the Awn,,, reached 25, the culture medium was 
centrifuged and the resultant supematant clarified by filtration through 
a 0.22pm tilter and concentrated by ultrafiltration on a membrane with 
a cut-off weight of 10 kDa. The fusion proteins were purified using an 
IaG-Seoharose 6FF column (Pharmacia) according to 1211 followed bv 
a-chromatographic step onto a MonoS 5/5 colt&r -(Pharmacia) to 
which we applied a 35 min linear gradient from 0 to 70% of eluent B 
(eluent A, 10 mM ammonium acetate, pH 5.6; eluent B, 1.5 M ammo- 
nium acetate, pH 5.6). Fusion proteins were then cleaved by cyanogen 
bromide in HCl 0.1 N at room temperature for 24 h and the resulting 
recombinant oxins were finally purified onto a MonoS 5/5 column 
using a 60 min linear gradient from 20 to 70% of eluent B (Eluent A, 
10 mM ammonium acetate, pH 7.3. Eluent B, 1.5 M ammonium ace- 
tate, pH 7.3) and a flow rate of 0.8 ml/min. 
2.6. Binding to rat brain synaptosomes 
Recombinant proteins were used in competition binding assays with 
[‘251]-dendrotoxin I (DpI) (100-250 Ci/mmol) or [‘251]a-dendrotoxin 
(DTx) (Amersham: 2000 Ci/mmol) as radioactive tracers. Rat brain 
synaptdsomes were’prepared from the brains of 200-250 male Sprague- 
Dawley rats as described in [28]. For the binding assay, synapatosomal 
membranes were incubated for 30 min at room temperature with 1 nM 
of labelled toxin in presence of increasing concentrations (lo-” to lo-’ 
M) of competitor. K, values were calculated following the Cheng and 
Prusoff method [29]. 
2.7. Chick biventer cervicis preparations 
Twitch tension experiments were performed using chick biventer 
cervicis and associated nerves, isolated from 4- to I-day-old chicks 
killed by exposure to anaesthetic halothane [30]. Isolated muscles were 
mounted in a 10 ml tissue bath containing physiological salt solution 
at 33°C with a resting tension that produced a maximum twitch. The 
motor nerve was stimulated every 10 s with pulses of 0.2 ms duration 
and a voltage greater than that which produced a maximal twitch. 
Details are given in [31]. 
2.8. Peptide sequencing of natural a-DTx 
100 pg of natural DTx were denatured, reduced and blocked with 
4-vinylpyridine as recommended by Applied Biosystems. They were 
then cleaved for 6 h at 37°C by 5 pg of endoproteinase Lys-C (Boehrin- 
ger-Mannheim) in 200 ~1 of 25 mM Tris-HCl, pH 8.5; 1 mM EDTA. 
Resulting peptides were separated by reverse-phase HPLC onto a C,, 
column (Vydac; 10 mm, 250 x 4.6 mm) using a 50 min linear gradient 
from 0 to 50% of eluent B (eluent A, TFA 0.1% in water; eluent B, TFA 
0.1% in water/acetonitrile 5O:SO). Each fraction was then submitted to 
amino acid composition analysis and Edman degradation. 
2.9. Central toxicity and LD,, determination 
For lethal dose 50 (LD,,) determination, groups of five to sixteen 
female Swiss mice (23.4 f 3.0 g) were injected intracerebroventricularly 
(i.c.v.) under light diethyl ether anaesthesia with 2 to 10 ng of toxin per 
g of body weight (2 to 10 ~1 in solution in NaCl 0.9%). LD,, was 
established after 48 h survival. 
For central toxicity comparison, DTx and recombinant mutated 
DTx (twice the LD,, of a-DTx in 10 ~1) were injected i.c.v. to groups 
of eight animals (22.9 + 1.3 g). The animals were allowed to recover 
consciousness and the times from injection of samples to the onset of 
symptoms (epileptiform activity, abnormal posturing.) and to death 
were measured. 
3. Results and discussion 
3.1. Synthetic genes and expression vector construction 
The first objective of this work was to design an appropriate 
expression vector for the wild-type DTx. The nucleotide se- 
quence of a synthetic gene encoding recombinant DTx was 
therefore designed on the basis of its published amino acid 
sequence [7] using usable codons in E coli [32]. Since natural 
DTx possesses a pyroglutamate at its N-terminal end, we 
introduced a codon for glutamine at the first position of the 
synthetic gene with the view to generate a pyroglutamic acid in 
the recombinant DTx, under acid conditions. Since there was 
no methionine in the sequence of DTx, we introduced a 
cyanogen bromide cleavage site in the fusion proteins by insert- 
ing a methionine codon at position - 1 of the gene encoding the 
recombinant toxin. We also flanked our construction with re- 
striction sites (including EcoRI and PstI) in order to clone it 
into pEZZ 18 [22,23], avector which is well suited for producing 
disulfide-containing proteins in E. coli [20,21]. The resulting 
expression vector ZZ-DTx encodes the protein A signal peptide 
followed by two IgG binding domains (15 kDa) linked to the 
recombinant oxin moiety (7 kDa) by a six amino acid peptide 
(Val-Asp-Ala-Asp-Ser-Met). 
It was previously proposed that conserved positively charged 
residues might contribute to the establishment of the interac- 
tion between DTx and potassium channels [14-161. In particu- 
lar, the lysine triplet 28-30 was suggested to play some critical 
function in this interaction. As shown on Fig. 1, this triplet is 
localized at the base of the molecule which clearly adopts the 
well-known pear shape of BPTI [lo]. We substituted the lysine 
triplet by the sequence Ala-Ala-Gly (AAG), and this choice 
resulted from an examination of a chart of amino acid se- 
quences of various dendrotoxins and their non-toxic homo- 
logues [5,33]. The recombinant mutant was produced in E. coli 
from a synthetic gene encoding DTx in which the three lysines 
were mutated into AAG, according to an approach similar to 
that used for production of the wild-type DTx. The resulting 
expression vector was called ZZ-DTx-AAG. 
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Fig. 1. Stereo view of the structure of DTx. The figure shows the structure of the toxin according to [lo]. The side chains of mutated residues 
(positions 12, 28, 29 and 30), as well as all additional positively charged residues, are shown. The disulfide bridges are stippled. 
3.2. Production of the fusion proteins 
The recombinant fusion proteins resulting from expression 
of ZZ-DTx and ZZ-DTx-AAG were mainly found in the cul- 
ture medium of bacterial suspensions, as expected for pEZZ 
expression vectors [22,23]. Chromatography on an IgG Sepha- 
rose column yielded proteins having the molecular weight (22 
kDa) expected for the fusion proteins. These proteins were, 
however, contaminated by lower molecular weight proteins 
which result from degradation of fusion proteins, as previously 
discussed [20,21]. These side products were removed by cation- 
exchange chromatography as described in section 2. As indi- 
cated by amino acid composition analyses, we found 1 mg and 
1.5 mg fusion proteins per 1 of culture for ZZ-DTx-AAG and 
ZZ-DTx, respectively. 
3.3. Purification and characterization of recombinant toxins 
Recombinant DTx and DTx-AAG resulted from cyanogen 
bromide cleavage of fusion proteins with a yield close to 65%. 
They were purified by cation-exchange chromatography. As 
shown in Fig. 2, however, each recombinant protein was recov- 
ered as two isoforms (peaks 1 and 2) having the same molecular 
weight and amino acid compositions but, as indicated by 
Edman degradation, differing at their N-terminal residue. One 
isoform has its N-terminal blocked (peak 1) while the other 
possesses an N-terminal glutamine (peak 2). Mass determina- 
tion revealed an 18 unit mass difference between the two 
isoforms of the wild-type and mutated recombinant DTxs. This 
is in agreement with the loss of an -NH: moiety and with the 
presence of a pyroglutamate residue formed by acidic cyclisa- 
tion of the N-terminal glutamine in the lighter isoforms. Fi- 
nally, sequencing was investigated until position 33 for the 
unblocked mutant toxin, and we thus assessed the effectiveness 
of the introduced mutations. Therefore, two isofotms of each 
recombinant protein were produced. They were called rDTx 
and rDTx-AAG for proteins having an N-terminal pyrogluta- 
mate residue and rQDTx and rQDTx-AAG for proteins having 
a free N-terminal glutamine residue. Since the circular dichroic 
spectra of the natural, recombinant wild-type and mutated 
DTxs were superimposable (not shown), we conclude that all 
these proteins have a similar content in secondary structure, 
suggesting that they all adopt a folding similar to that of the 
natural DTx. 
3.4. Chemical differences between natural and recombinant 
wild-type toxin 
While purifying rDTx, we observed that this protein eluted 
from the cation-exchange column later than DTx isolated 
from the venom, indicating its more basic nature. This was 
surprising since their amino acid compositions and masses were 
similar, within the experimental errors. We thus anticipated 
that this elution difference could be associated with an amino 
acid sequence difference not detectable by amino acid composi- 
tion analyses such as Am/Asp or Gln/Glu. This prompted us 
to re-investigate the amino acid sequence of DTx isolated 
from the venom of Dendroaspis angusticeps. For this purpose, 
we generated five toxin fragments using endoproteinase Lys C 
which were purified by RP-HPLC and characterized by amino 
acid composition analysis and sequencing. These fragments 
correspond to the published sequence of DTx [7] from resi- 
dues 6-59, except hat residue 12 was found to be an aspartate 
instead of the expected asparagine. Clearly, the natural DTx 
that we used as a control is an isoform of that described by 
Joubert and Taljaard [7l and Karlsson (cited in [2]). Therefore, 
DTx, as it is isolated from the venom of a Dendroaspis angus- 
ticeps from East Africa, has an amino acid sequence that is 
distinct from the one to which we currently refer to. Determina- 
tion of new isoforms of toxins is not so surprising because of 
the great diversity of toxic and non-toxic homologous proteins 
Table 1 
Inhibition of radioactive toxin binding to rat brain synaptososmal 
membranes by natural and recombinant dendrotoxins 
Toxin K WI) 
DTx 1.14 f 0.15 
rDTx 1.37 f 0.36 
rQDTx 0.22 r 0.01 
DTx 0.62 f 0.12 
rDTx-AAG 2.13 + 0.06 
rQDTx-AAG 4.76 + 0.24 
K, values are calculated from Fig. 2 as described in section 2. 
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Fig. 2. Purification of recombinant DTx. Products resulting from cleavage by CNBr of the fusion protein were separated onto a MonoS 5/5 column 
(Pharmacia). Eluent A, ammonium acetate 10 mM, pH 7.3. Eluent B, ammonium acetate 1.5 M, pH 7.3. Flow rate 0.8 ml/mim. The inset shows 
an SDS-PAGE (20% acrylamide) of fractions 1 and 2. Lane M, molecular mass markers (from top to bottom) 16.95, 14.4, 8.16 and 6.2 kDa. Lane 
T, natural DTx. Lane 1, protein from fraction 1; lane 2, from fraction 2. The samples were boiled for 5 min in sample buffer containing 2.5% SDS 
and 5% 2-mercautoethanol and then incubated for 30 min with 10 mM iodoacetamide at 20°C before loading. The gel was stained with Coomassie 
blue. 
already described in the venoms of the snakes of the mamba 
genus [5,6,33]. More than 70 peptides in the molecular weight 
range 6000-9000 Da have been recently reported in the venom 
of Dendroaspis polylepis [34]. 
3.5. Biological properties of recombinant toxins 
In a first series of experiments, we investigated the capacity 
of recombinant DTxs to compete with radioactive tracers for 
binding to rat brain synaptosomal membranes. We used radio- 
active DTx or its homolog, DpI, as radioactive tracers, and 
found similar Ki values for unlabelled DTx. Either tracer could 
therefore be used to probe the relative affinity of DTx and its 
mutants. As shown in Fig. 3, binding of these tracers to synap- 
tosomes is fully inhibited by all recombinant DTxs. More pre- 
cisely, Table 1 shows that DTx and rDTx which only differ by 
the nature of the residue at position 12 (aspartate in natural 
DTx and asparagine in rDTx) are characterized by similar K, 
values. This result indicates not only that the recombinant 
protein is biologically active but also that residue 12 is unlikely 
to be critical for the binding of DTx to potassium channels. 
rDTx-AAG was characterized by an approximately 4 fold in- 
crease in the K, value as compared to DTx. Such a variation 
in a Ki value is too small to be indicative of the effective partic- 
ipation of the mutated residues to the establishment of the 
interactions between the protein and a specific partner as 
shown, for instance, in the case of an antibody-antigen com- 
plex [35]. More likely, such residues are likely to be localized 
in the vicinity of the interacting zone [36]. As a further illustra- 
tion of the possible fluctuation of K, values, we found that 
changing the pyroglutamic residue at the N-terminus of rDTx 
and rDTx-AAG into a positively charged glutamine, as in 
rQDTx and rQDTx-AAG, induced a decrease and an increase 
in K, values, by factors of 5 and 2, respectively (see Table 1). 
The reason for such a fluctuation is unclear. Therefore, on the 
basis of competition experiments, we conclude that the three 
charges at positions 28-30, as well as the asparagine-12 or the 
N-terminus positive charge, are unlikely to be implicated in the 
contact area. 
In a second step, the effect of DTxs and the mutants on 
twitch tension of indirectly stimulated chick biventer cervicis 
nerve muscle preparations were measured. All recombinant 
DTxs increased tension in a manner similar to that of the 
natural DTx (not shown). These results agree with the binding 
inhibition experiments and confirm that the lysine triplet is not 
essential for the binding to potassium channels. As a control, 
we checked that there was no change in postsynaptic sensitivity 
and therefore that the observed effect presumably resulted from 
blockage of neuronal potassium channels. 
Finally, central neurotoxicity of natural and mutated DTxs 
were assayed by intracerebroventricular (i.c.v.) injections. Min- 
imum lethal doses of DTx by i.c.v. injection have been re- 
ported in rat and chick [37,38] (2.5 ng and 19 rig/g of body 
weight, respectively) but not in mice. We found the LD,, to be 
approximately equal to 5 rig/g,, a value 5000 times lower than 
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Fig. 3. Competition binding assays to rat brain synaptosomes. Competition between radioactive DTx (1 nM; the specific radioactivity varied from 
batch to batch between 100 and 2000 Wmmol) and various amounts of natural of recombinant DTxs. Left panel: native (m) and recombinant wild-type 
DTx (rDTx: o and rQDTx: 0). The radioactive tracer was [‘251]dendrotoxin I. Right panel: native (A) and recombinant mutated DTx (rDTx-AAG, 
O; and rQDTx-AAG, 0). The radioactive tracer was [‘251]cz-dendrotoxin. Points with error bars are the means f S.E.M. for three experiments. 
that obtained by the peripheral injection route [7]. As expected, 
the delay between the injection of the toxin into the brain and 
the appearance of the convulsive symptoms and the death was 
dose-dependent. Each mutant isoform was therefore injected at 
a dose equal to twice the LD,, of DTx and the delays between 
i.c.v. injection and appearance of symptoms and death were 
determined. As shown in Table 2, rDTx-AAG and rQDTx- 
AAG were both lethal in mice but the onset of symptoms and 
time of death were slightly later than those observed with DTx 
and rDTx, and this difference agrees with that observed for K, 
values (Table 1). Such a relationship between the Ki values and 
the minimal lethal doses or between the dose of toxin and the 
onset of symptoms and death have also been reported in rats 
by i.c.v. injection of other facilitatory toxins [37,38], and further 
confirms that the effects observed in vitro, even when they are 
minor, most probably reflect the more complex events that 
occur in vivo. 
Table 2 
Central toxicity of natural DTx, rDTx-AAG and rQDTx-AAG 
mutants 
Toxin Onset of symptoms 
(min) 
Death 
(min) 
DTx 2.5 f 1 22.5 f 1 
rDTx-AAG 6.4 f 2.7 39 f 21 
rQDTx-AAG 7.7 f 1.5 62 f 21 
Toxicity after i.c.v. injection into female Swiss mice (lots of eight ani- 
mals) of natural DTx (9.44 + 0.81 rig/g injected into 22.9 + 1.8 g mice), 
rDTx-AAg (9.08 f 0.43 rig/g injected into 18.8 f 0.9 g mice) and 
rQDTx-AAG mutant (9.07 k 0.30 rig/g injected into 23.1 f 0.3 g mice). 
Average time f S.E.M. for the onset of symptoms and to death are 
reported. 
4. Conclusion 
Recombinant toxins and their associated large number of 
possible mutants constitute important tools to delineate the site 
by which toxins recognize their complex targets, i.e. receptors, 
ion channels, etc. [16,36,3942]. Identification of interacting 
sites between various potassium channels and specific toxins 
like charybdotoxin [4@42], DpI [16] or a-dendrotoxin (this 
work) is now rapidly progressing. All residues of 
charybdotoxin, a 37 amino acids toxin from scorpion Leiurus 
quinquestriatus quinquestriatus that recognizes Ca2+-activated 
K’ channels, were submitted to individual mutagenesis and it 
was found that substantial affinity decreases occurred when 
mutations were made at 8 positions, among which 3 are occu- 
pied by positively charged residues, 3 by hydrophobic ones and 
2 by residues with hydrogen bonding capacity [40,41]. Since 
DTx’s compete with charybdotoxin in various assays, it was 
tempting to anticipate that DTx’s may also involve positively 
charged residues. This was all the more an attractive idea as it 
was specifically suggested that the triplet Lys-28, Lys-29, Lys- 
30, may be associated with the specific action of the toxins 
[14-161. Using recombinant DTx we provide clear evidence, 
however, that this triplet is unlikely to constitute a major ele- 
ment for the functional properties of DTx. As shown in Fig. 
1, however, several other positively charged residues of DTx are 
possible candidates to establish a binding with K’ channel. 
Production and characterization of new mutants is now in 
progress to identify the residues by which DTx establishes uch 
contact. Clearly, comparison of the functional sites of DTx 
and charybdotoxin should greatly help us to understand the 
molecular basis for their functional similarities and differences 
and hence to design drugs with appropriate fine specificities. 
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